AAV gene therapy
| 5 min read
Emerging optogenetic, gene, and cell therapies are moving beyond single-gene treatments, offering hope for a broader range of patients with retinitis pigmentosa.
| 3 min read
These latest deals give Lilly a complementary portfolio of life-changing therapies and scalable gene therapy platforms.
| 4 min read
Another biotech retreats from AAV, a promising antibiotic, a paused CRISPR trial, and more led the news this week.
| 5 min read
After a decade of promise, AAV therapies are now confronting economic, clinical, and regulatory hurdles.
| 3 min read
Papzimeos is the first FDA-approved therapy for recurrent respiratory papillomatosis, a rare HPV-driven disease that has long forced patients into repeated surgeries.
| 2 min read
First commercially available cell culture solution for HEK293 cells and perfusion, optimized for high cell density, intensified processes and perfusion cultures.
| 3 min read
New dual AAV vector delivery overcomes challenges in delivering large genes.
| 8 min read
New gene therapies in clinical trials seek to treat Alzheimer’s disease and heal the brain with a dose of helpful genetic material.
| 9 min read
Rett syndrome currently has no cure. Now, innovations in gene therapy bring the possibility of treating the root cause of the disease closer than ever before.
| 4 min read
Previous genome editing techniques only work when delivered early in life. This approach could help preserve hearing that is lost later on.
